MXPA02012890A - Uso de compuestos de indol sustituidos para incrementar la actividad de oxido nitrico sintasa. - Google Patents
Uso de compuestos de indol sustituidos para incrementar la actividad de oxido nitrico sintasa.Info
- Publication number
- MXPA02012890A MXPA02012890A MXPA02012890A MXPA02012890A MXPA02012890A MX PA02012890 A MXPA02012890 A MX PA02012890A MX PA02012890 A MXPA02012890 A MX PA02012890A MX PA02012890 A MXPA02012890 A MX PA02012890A MX PA02012890 A MXPA02012890 A MX PA02012890A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- nitric oxide
- oxide synthase
- synthase activity
- increasing nitric
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21618700P | 2000-07-06 | 2000-07-06 | |
PCT/US2001/021083 WO2002003991A2 (en) | 2000-07-06 | 2001-06-29 | Use of substituted indole compounds for increasing nitric oxide synthase activity |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA02012890A true MXPA02012890A (es) | 2003-10-24 |
Family
ID=22806070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA02012890A MXPA02012890A (es) | 2000-07-06 | 2001-06-29 | Uso de compuestos de indol sustituidos para incrementar la actividad de oxido nitrico sintasa. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20020022617A1 (es) |
EP (1) | EP1296674A2 (es) |
JP (1) | JP2004502734A (es) |
CN (1) | CN1635885A (es) |
AU (1) | AU7178301A (es) |
BR (1) | BR0112360A (es) |
CA (1) | CA2414111A1 (es) |
MX (1) | MXPA02012890A (es) |
WO (1) | WO2002003991A2 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ537051A (en) * | 2002-06-13 | 2007-11-30 | Wyeth Corp | Use of bazedoxifene in an extended dosage treatment regimen |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
CN101277949A (zh) | 2005-04-22 | 2008-10-01 | 阿兰托斯制药控股公司 | 二肽基肽酶-ⅳ抑制剂 |
ZA200809659B (en) * | 2006-04-13 | 2010-03-31 | Neuraxon Inc | 1,5 and 3,6-substituted indole compounds having NOS inhibitory activity |
ES2400294T3 (es) * | 2006-12-11 | 2013-04-08 | 3D Matrix, Inc. | Composiciones y métodos para protección y regeneración del tejido cardiaco |
CN108366996B (zh) | 2015-10-01 | 2021-04-09 | 奥列马制药公司 | 四氢-1H-吡啶[3,4-b]吲哚类抗***药物 |
EP3386500B1 (en) | 2015-12-09 | 2022-09-07 | The Board of Trustees of the University of Illinois | Benzothiophene-based selective estrogen receptor downregulators |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
AU2017290748A1 (en) | 2016-07-01 | 2019-01-17 | G1 Therapeutics, Inc. | Pyrimidine-based antiproliferative agents |
WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
JP7229162B2 (ja) | 2017-01-06 | 2023-02-27 | ジー1 セラピューティクス, インコーポレイテッド | 癌の治療に対する併用療法 |
CN110461853A (zh) | 2017-02-10 | 2019-11-15 | G1治疗公司 | 苯并噻吩***受体调节剂 |
CN110913861B (zh) | 2017-06-29 | 2024-01-09 | G1治疗公司 | G1t38的形态学形式及其制造方法 |
CN107951034B (zh) * | 2017-12-01 | 2021-03-23 | 郑州拓洋生物工程有限公司 | 维生素泡腾制剂及其制备方法 |
CN113453679A (zh) | 2018-12-20 | 2021-09-28 | C4医药公司 | 靶向蛋白降解 |
WO2024030968A1 (en) | 2022-08-03 | 2024-02-08 | Brystol-Myers Squibb Company | Compounds for modulating ret protein |
WO2024097980A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein inhibitors |
WO2024097989A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein degraders |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW397821B (en) * | 1996-04-19 | 2000-07-11 | American Home Produits Corp | 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof |
US5880137A (en) * | 1996-04-19 | 1999-03-09 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
DE69707189T2 (de) * | 1996-04-19 | 2002-06-20 | American Home Prod | Östrogene Verbindungen |
US5811437A (en) * | 1996-05-21 | 1998-09-22 | Eli Lilly And Company | Methods of increasing nitric oxide synthesis |
WO1998048797A1 (en) * | 1997-04-30 | 1998-11-05 | Eli Lilly And Company | Antithrombotic agents |
US6465445B1 (en) * | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
AU7896100A (en) * | 1999-10-14 | 2001-04-23 | Endorecherche Inc. | Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance |
CO5271696A1 (es) * | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para reducir la morbilidad y el riesgo de mortalidad |
CO5251465A1 (es) * | 2000-01-26 | 2003-02-28 | Pfizer Prod Inc | Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol |
WO2001054699A1 (en) * | 2000-01-28 | 2001-08-02 | Endorecherche, Inc. | Selective estrogen receptor modulators in combination with estrogens |
-
2001
- 2001-06-29 CA CA002414111A patent/CA2414111A1/en not_active Abandoned
- 2001-06-29 CN CNA018150926A patent/CN1635885A/zh active Pending
- 2001-06-29 US US09/896,360 patent/US20020022617A1/en not_active Abandoned
- 2001-06-29 WO PCT/US2001/021083 patent/WO2002003991A2/en not_active Application Discontinuation
- 2001-06-29 EP EP01950824A patent/EP1296674A2/en not_active Withdrawn
- 2001-06-29 BR BR0112360-2A patent/BR0112360A/pt not_active Application Discontinuation
- 2001-06-29 MX MXPA02012890A patent/MXPA02012890A/es unknown
- 2001-06-29 AU AU7178301A patent/AU7178301A/xx active Pending
- 2001-06-29 JP JP2002508445A patent/JP2004502734A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2002003991A2 (en) | 2002-01-17 |
WO2002003991A3 (en) | 2002-07-04 |
JP2004502734A (ja) | 2004-01-29 |
EP1296674A2 (en) | 2003-04-02 |
US20020022617A1 (en) | 2002-02-21 |
CA2414111A1 (en) | 2002-01-17 |
BR0112360A (pt) | 2003-05-06 |
CN1635885A (zh) | 2005-07-06 |
AU7178301A (en) | 2002-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB0031179D0 (en) | Nitric oxide synthase inhibitors | |
MXPA02012890A (es) | Uso de compuestos de indol sustituidos para incrementar la actividad de oxido nitrico sintasa. | |
ZA98179B (en) | Nitric oxide synthase inhibitors. | |
GB9811599D0 (en) | Nitric oxide synthase inhibitors | |
MX243820B (es) | Oxido de metal particulado. | |
EP1429829A4 (en) | NITROGEN OXIDE GENERATION | |
MXPA03002410A (es) | 4-amino-quinazolinas. | |
MXPA01011516A (es) | Incinerador de pared radiante de bajo nox. | |
ZA200007669B (en) | Insert. | |
EG23262A (en) | Delta -pyrrolines. | |
MXPA01010764A (es) | Ensamble de quemador de emisiones bajas en nox y metodo para reducir el contenido de nox de gas de combustion de alto horno. | |
HK1056872A1 (en) | Indoloquinazolinones. | |
MXPA03001591A (es) | Derivados y analogos de 10-aril-11-h-benzo(b) fluorena para uso medicinal. | |
MXPA03001877A (es) | 2-guanidin-4-arilquinazolinas. | |
MXPA03002668A (es) | Guanidinas de sulfonilo. | |
MXPA03003376A (es) | Celda. | |
MXPA03005714A (es) | Sulfamidotienopirimidinas. | |
MXPA03002411A (es) | 4-amino-quinazolinas. | |
AU2001282746A1 (en) | Novel phenylheteroazetidines, useful as nitric oxide synthase inhibitors | |
AU2001234538A1 (en) | Nitric oxide synthase gene diagnostic polymorphisms | |
MXPA01006792A (es) | Bateria. | |
MXPA03005494A (es) | Benzoilpiridazinas. | |
HK1061560A1 (en) | Triazolo-epothilones. | |
HK1038207A1 (en) | Abrasive. | |
AU2002350575A1 (en) | Selective neuronal nitric oxide synthase inhibitors |